Canada’s Drug Agency | Drugs, Health Technologies and Systems.

caplacizumab

Details

Generic Name:
caplacizumab
Project Status:
Pending
Therapeutic Area:
Thrombotic thrombocytopenic purpura (aTTP)
Manufacturer:
Sanofi-Aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cablivi
Project Line:
Reimbursement Review
Project Number:
SR0912-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Cablivi ​(caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Submission Type:
Resubmission
Fee Schedule:
Pending
Indications:
Cablivi ​(caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 7, 2025